Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR)

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million)

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW.

Arcoma AB (“Arcoma” or the “Company”) (Nasdaq First North Growth Market: ARCOMA) today announces that the Board of Directors has resolved on a directed share issue of a total of 1,122,950 new shares (the “New Shares”) for the funds managed by Eiffel Investment Group, based on the authorization granted by the Annual General Meeting held on 14 May 2025 (the “Directed Share Issue”). Through the Directed Share Issue, the Company will raise approximately 11.0 MSEK before transaction-related costs.

The Directed Share Issue

The Board of Directors of Arcoma has today resolved on the Directed Share Issue of 1,122,950 New Shares, based on the authorization from the Annual General Meeting on 14 May 2025. The issue has been fully subscribed by the funds FCPI Alto Innovation 2021 and FCPI Alto Innovation 2023 managed by the French institutional investor Eiffel Investment Group (“Eiffel”), which will thereby become one of Arcoma’s largest shareholders. The subscription price for the New Shares is 9.76 SEK per share, corresponding to a premium of approximately 4.3 percent compared to the closing price of Arcoma’s shares on Nasdaq First North Growth Market on 24 June 2025.

Through the Directed Share Issue, the Company will raise approximately 11.0 MSEK before transaction-related costs. Arcoma intends to use the net proceeds to expand its sales resources, invest further in product development and innovation, and accelerate its acquisition strategy.

Mattias Leire, CEO, Arcoma comments:

“We are very pleased to welcome Eiffel Investment Group as a new strategic shareholder in Arcoma. That an internationally recognized investor with deep expertise in innovation chooses to invest in our company is a strong vote of confidence in our strategy and business model. Eiffel initiated the dialogue after following our progress and expressing appreciation for how we have strategically built a scalable business model. They have particularly highlighted our ability to translate this strategy into tangible results, through improved profitability, a strengthened balance sheet, and a clear path toward long-term value creation. This confirms that our methodical approach is appreciated by investors who share our view on sustainable growth. With this capital injection, we are accelerating our growth journey. We will strengthen our market presence through expanded sales resources, continue investing in product development and innovation, and actively accelerate our acquisition efforts. The combination of a strengthened financial position and a new strategic owner provides the right conditions to realize Arcoma’s full potential.”